Hidden Brain Cells Called Oligodendrocytes Emerge as Unexpected Drivers of Parkinson’s Disease

Parkinson’s disease has long been told as a story about dopamine neurons: the slow, relentless death of cells in the substantia nigra that produce the brain’s movement chemical, leaving patients with tremor, stiffness and slowness. But a sweeping new study published in Nature Communications argues that this narrative is incomplete. By mapping gene activity and metabolism across the brain with unprecedented spatial precision, a research team led by scientists at Guangzhou Medical University has uncovered a specialized population of oligodendrocytes — the cells best known for insulating nerve fibers — that appears to fan the flames of Parkinson’s pathology rather than merely witness it.

The study, which combined single-nucleus RNA sequencing, spatial transcriptomics and spatial metabolomics in male mice carrying the human A53T alpha-synuclein mutation, represents one of the most comprehensive attempts yet to chart how Parkinson’s disease reshapes the brain’s immunometabolic landscape. Alpha-synuclein is the protein that clumps into the characteristic Lewy bodies of Parkinson’s, and understanding how this pathology propagates through brain tissue — cell by cell, region by region — has become one of the field’s central quests. The team supplemented the mouse work with an independent model using adeno-associated virus to overexpress alpha-synuclein, and crucially, with human midbrain and cerebrospinal fluid samples from patients, giving the findings a translational anchor that mouse studies alone often lack.

What the researchers found was a distinct disease-associated oligodendrocyte lineage, marked by elevated expression of two genes: Il33, which encodes the signaling molecule interleukin 33, and Kirrel3, a gene involved in synaptic and cellular adhesion. This population was not a fleeting artifact of one model or one disease stage. It expanded progressively as pathology accumulated in both the transgenic A53T mice and the viral overexpression model, suggesting that the emergence of these altered oligodendrocytes tracks closely with the burden of misfolded alpha-synuclein in the brain.

The significance of interleukin 33 lies in where it acts. The team found that the signaling molecule itself was upregulated in oligodendrocytes, while its receptor, known as ST2, was upregulated in microglia — the brain’s resident immune cells. This arrangement creates a communication channel between two cell types that are rarely cast as leading actors in Parkinson’s disease. Oligodendrocytes, stressed or transformed by the surrounding pathology, appear to send inflammatory signals through interleukin 33, and microglia, primed by elevated receptor expression, appear poised to receive them and respond.

To test whether this crosstalk actually matters for the disease process, the researchers performed bidirectional manipulation of the Il33 gene in oligodendrocytes — turning it up in some experiments and down in others. The results were striking. Altering oligodendrocyte interleukin 33 changed the activation state of microglial ST2 signaling, and it also changed two of the most consequential measures in Parkinson’s research: the burden of insoluble alpha-synuclein in the brain and the motor performance of the animals. In other words, a signal originating in the myelin-forming cells of the brain influenced both the molecular hallmark of the disease and the behavioral symptoms it produces.

Beyond the oligodendrocyte story, the spatial multi-omics approach revealed a second major theme: metabolic dysregulation. In the substantia nigra and the ventral tegmental area — the two midbrain regions that house the dopamine neurons most affected in Parkinson’s disease — the team found that transcriptomic and metabolomic changes converged on lipid-related and glutamate-related pathways. This convergence is notable because it links two processes that have each attracted attention in neurodegeneration research separately: disturbances in lipid metabolism, which have been increasingly implicated in alpha-synuclein aggregation, and glutamate signaling, the brain’s primary excitatory neurotransmitter system, whose excess can become toxic to neurons.

The spatial dimension of the study is what sets it apart technically. Traditional single-cell sequencing requires dissociating tissue, which strips away the geographic context that is often essential for understanding disease. By pairing single-nucleus RNA sequencing with spatial transcriptomics — which preserves the physical location of gene expression — and spatial metabolomics, which maps small metabolic molecules across tissue sections using mass spectrometry imaging, the researchers could see not just which cells were altered but where in the diseased brain those alterations clustered, and how the chemical environment of specific regions shifted with disease progression.

The human data provide perhaps the most clinically resonant finding. Both interleukin 33 and its receptor ST2 were elevated not only in mouse models but in human Parkinson’s disease midbrain tissue and in patients’ cerebrospinal fluid. That elevation in cerebrospinal fluid is particularly intriguing, because the fluid surrounding the brain and spinal cord can in principle be sampled in living patients through a lumbar puncture. If the mouse findings translate, proteins in this signaling axis could eventually serve as accessible biomarkers reflecting the state of a cellular pathway deep inside the brain.

The authors emphasize that their dataset constitutes a spatially resolved resource for the broader research community, cataloging how the immunometabolic landscape of the Parkinson’s brain changes across disease stages. Such resources matter because Parkinson’s drug development has been dominated for decades by dopamine-replacement strategies that treat symptoms without slowing the underlying neurodegeneration. If oligodendrocyte interleukin 33–ST2 signaling genuinely modulates alpha-synuclein burden and motor decline, it offers a new node at which disease modification might be attempted — one that targets the glial environment surrounding vulnerable neurons rather than the neurons themselves.

Important caveats remain. The mouse work was conducted exclusively in male animals, and sex differences are well documented in both Parkinson’s disease biology and immune signaling, so extending the findings to female models will be an essential next step. The published version is also an early-release, peer-reviewed article that remains subject to further editorial refinement. Nevertheless, the convergence of evidence — across two independent mouse models, multiple omics technologies, and human tissue and fluid samples — makes a compelling case that the cells once dismissed as passive insulation around nerve fibers may hold a key to understanding, and perhaps one day slowing, one of the world’s most common neurodegenerative diseases.

Subject of Research: Disease-associated oligodendrocytes and interleukin 33–ST2 immune signaling in Parkinson's disease

Article Title: Spatial multi-omics reveals disease-associated oligodendrocytes and metabolic dysregulation in male Parkinson’s disease mouse models

Article References: Zhu, Z., Xu, Z., Chen, M., Ding, L., Feng, D., Liang, F., Shu, H., Su, Z., Huang, X., Zhu, X., Liang, X., Huang, S., Xu, P., & Zhang, W. (2026). Spatial multi-omics reveals disease-associated oligodendrocytes and metabolic dysregulation in male Parkinson’s disease mouse models. Nature Communications. https://doi.org/10.1038/s41467-026-78051-5

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78051-5

Keywords: Parkinson's disease, oligodendrocytes, interleukin 33, ST2 receptor, alpha-synuclein, spatial transcriptomics, spatial metabolomics, microglia, substantia nigra, lipid metabolism, glutamate signaling, neurodegeneration